Yoshiaki Uyama

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 24

Top Topics

Acute Ischemic Stroke

Venous Thromboembolism

Top Venues

Therapeutic innovation & regulatory science

Pharmacoepidemiology and drug safety

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Masayasu Hidaka, Hideki Hanaoka, Yoshiaki Uyama
Different Development Strategies Affecting Japan's Drug lag between Japan-Based and Foreign-Based Companies. Therapeutic innovation & regulatory science 58 (4) (2024)
Haruka Shida, Maki Komamine, Kazuhiro Kajiyama, Takashi Waki, Hotaka Maruyama, Yoshiaki Uyama
Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan. PloS one 19 (1) (2024)
Kazuhiro Kajiyama, Maki Komamine, Naoya Horiuchi, Toyotaka Iguchi, Yoshiaki Uyama
PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage. Pharmacoepidemiology and drug safety 33 (9) (2024)
Masayasu Hidaka, Hideki Hanaoka, Yoshiaki Uyama
Different Development Strategies Affecting Japan's Drug lag between Japan-Based and Foreign-Based Companies. Therapeutic innovation & regulatory science (2024)
Yusuke Okada, Kazuhiro Kajiyama, Chieko Ishiguro, Takahiro Nonaka, Tomomi Komaki, Wataru Kuga, Noriyuki Komiyama, Toyotaka Iguchi, Naoya Horiuchi, Yoshiaki Uyama
Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET ® in Japan. The Journal of dermatological treatment 35 (1) (2024)
Haruka Shida, Maki Komamine, Kazuhiro Kajiyama, Takashi Waki, Hotaka Maruyama, Yoshiaki Uyama
Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan. PloS one 19 (1) (2024)
Haruka Shida, Maki Komamine, Kazuhiro Kajiyama, Takashi Waki, Hotaka Maruyama, Yoshiaki Uyama
Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan. PloS one 19 (1) (2024)
Yuki Kinoshita, Kazuhiro Kajiyama, Chieko Ishiguro, Takahiro Nonaka, Ryota Kimura, Yuki Kikuchi, Naoya Horiuchi, Toyotaka Iguchi, Yoshiaki Uyama
Characterizing Granulocytopenia Associated with Thiamazole in Patients with Hyperthyroidism Based on Real-World Data from the MID-NET in Japan. Clinical pharmacology and therapeutics 113 (4) (2023)
Yuki Kinoshita, Kazuhiro Kajiyama, Chieko Ishiguro, Takahiro Nonaka, Ryota Kimura, Yuki Kikuchi, Naoya Horiuchi, Toyotaka Iguchi, Yoshiaki Uyama
Characterizing granulocytopenia associated with thiamazole in patients with hyperthyroidism based on real-world data from the MID-NET® in Japan. Clinical pharmacology and therapeutics (2023)
Yuki Kinoshita, Kazuhiro Kajiyama, Chieko Ishiguro, Takahiro Nonaka, Ryota Kimura, Yuki Kikuchi, Naoya Horiuchi, Toyotaka Iguchi, Yoshiaki Uyama
Characterizing Granulocytopenia Associated with Thiamazole in Patients with Hyperthyroidism Based on Real-World Data from the MID-NET in Japan. Clinical pharmacology and therapeutics 113 (4) (2023)
Yuki Kinoshita, Kazuhiro Kajiyama, Chieko Ishiguro, Takahiro Nonaka, Ryota Kimura, Yuki Kikuchi, Naoya Horiuchi, Toyotaka Iguchi, Yoshiaki Uyama
Characterizing Granulocytopenia Associated with Thiamazole in Patients with Hyperthyroidism Based on Real-World Data from the MID-NET in Japan. Clinical pharmacology and therapeutics (2023)
Tomoaki Hasegawa, Sono Sawada, Tomoyuki Saito, Mei Kohama, Kazuhiro Kajiyama, Chieko Ishiguro, Takahiro Nonaka, Toshiyuki Okamura, Yukari Iwasaki, Takahiro Ueda, Toyotaka Iguchi, Naoya Horiuchi, Yoshiaki Uyama
Lower Risks of Gastrointestinal Perforation and Intestinal Obstruction in Patients with Atypical Antipsychotics in Comparison with Typical Antipsychotics Based on Real-World Data from the MID-NET ® in Japan. Therapeutic innovation & regulatory science (2023)
Yoko Aoi, Yuta Kato, Kunihito Asano, Yasuto Otsubo, Yoshiaki Uyama
Characteristics of Asian Participation in Multi-regional Clinical Trials Reviewed for Drug Approval in Japan: Opportunities for Collaboration Between South-East Asia, East Asia, and Japan. Therapeutic innovation & regulatory science (2023)
Atsushi Noguchi, Hideki Hanaoka, Yoshiaki Uyama
Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia. Therapeutic innovation & regulatory science 56 (3) (2022)
Sono Sawada, Kazuhiro Kajiyama, Haruka Shida, Ryota Kimura, Yuki Nakazato, Toyotaka Iguchi, Yukio Oniyama, Chieko Ishiguro, Yoshiaki Uyama
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Clinical and translational science (2022)
Masatoshi Tanigawa, Mei Kohama, Takahiro Nonaka, Atsuko Saito, Ado Tamiya, Hiroko Nomura, Yoko Kataoka, Masanobu Okauchi, Takashi Tamiya, Ryusuke Inoue, Masaharu Nakayama, Takahiro Suzuki, Yoshiaki Uyama, Hideto Yokoi
Validity of identification algorithms combining diagnostic codes with other measures for acute ischemic stroke in MID-NET®. Pharmacoepidemiology and drug safety 31 (5) (2022)
Tomoaki Hasegawa, Sono Sawada, Chieko Ishiguro, Takashi Ando, Kanae Kobayashi, Noriyuki Komiyama, Toyotaka Iguchi, Takahiro Nonaka, Yoshiaki Uyama
Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET ® Medical Information Database Network in Japan. Therapeutic innovation & regulatory science 56 (4) (2022)
Sono Sawada, Takashi Ando, Mai Hirano, Noriyuki Komiyama, Toyotaka Iguchi, Yukio Oniyama, Chieko Ishiguro, Yoshiaki Uyama
Effect of Hepatitis C Drugs on Blood Coagulability in Patients on Warfarin Using the Medical Information Database Network (MID-NET®) in Japan. Therapeutic innovation & regulatory science 55 (3) (2021)
Asami Ezaki, Akihiro Hirakawa, Hideki Hanaoka, Yoshiaki Uyama
Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis. Therapeutic innovation & regulatory science 55 (5) (2021)
Ayaka Hiramatsu, Hideki Hanaoka, Yoshiaki Uyama
Characteristics on Drug Safety Measures in Japan Stratified by System Organ Classes and Therapeutic Categories in Relation to the Approval Date. Therapeutic innovation & regulatory science 54 (6) (2020)
Mitsune Yamaguchi, Satomi Inomata, Sayoko Harada, Yu Matsuzaki, Maiko Kawaguchi, Mayuko Ujibe, Mari Kishiba, Yoshiaki Fujimura, Michio Kimura, Koichiro Murata, Naoki Nakashima, Masaharu Nakayama, Kazuhiko Ohe, Takao Orii, Eizaburo Sueoka, Takahiro Suzuki, Hideto Yokoi, Fumitaka Takahashi, Yoshiaki Uyama
Establishment of the MID-NET® medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiology and drug safety 28 (10) (2019)
Masatoshi Tanigawa, Yoko Kataoka, Takayoshi Kishino, Mei Kohama, Yoshiaki Uyama, Yasuyuki Suzuki, Hideto Yokoi
Identification of gastrointestinal perforation based on ICD-10 code in a Japanese administrative medical information database and associated drug exposure risk factors. Pharmacoepidemiology and drug safety 28 (7) (2019)
Maki Komamine, Kazuhiro Kajiyama, Chieko Ishiguro, Yoshiaki Uyama
Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study. Pharmacoepidemiology and drug safety 28 (9) (2019)
Kaori Yamada, Maori Itoh, Yoshiaki Fujimura, Michio Kimura, Koichiro Murata, Naoki Nakashima, Masaharu Nakayama, Kazuhiko Ohe, Takao Orii, Eizaburo Sueoka, Takahiro Suzuki, Hideto Yokoi, Chieko Ishiguro, Yoshiaki Uyama, null null
The utilization and challenges of Japan's MID-NET® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies. Pharmacoepidemiology and drug safety 28 (5) (2019)